Page last updated: 2024-10-17

lactic acid and Hereditary Optic Atrophy

lactic acid has been researched along with Hereditary Optic Atrophy in 5 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Research Excerpts

Excerpt	Relevance	Reference
"In both cases, Leber's congenital amaurosis was diagnosed."	1.29	Leber's congenital amaurosis associated with mitochondrial dysfunction. ( Arenas, J; Beiras-Iglesias, A; Campos, Y; Castro-Gago, M; Eirís-Puñal, J; Maroto, S; Pintos-Martínez, E, 1996)

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cornelissen, JC	1
Wanders, RJ	1
Bolhuis, PA	1
Bleeker-Wagemakers, E	1
Oostra, RJ	1
Wijburg, FA	1
Montagna, P	2
Plazzi, G	1
Cortelli, P	1
Carelli, V	2
Lugaresi, E	2
Barboni, P	2
Fiocchi, M	1
Castro-Gago, M	1
Pintos-Martínez, E	1
Beiras-Iglesias, A	1
Maroto, S	1
Campos, Y	1
Arenas, J	1
Eirís-Puñal, J	1
Ninomiya, T	1
Yamazaki, H	1
Munakata, S	1
Yoshino, H	1
Sato, T	1
Zacchini, A	1
Mancini, R	1
Monari, L	1
Cevoli, S	1
Liguori, R	1
Sensi, M	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy[NCT01267422]				9 participants (Actual)	Interventional	2011-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Intraocular Pressure;

(NCT01267422)
Timeframe: Up to 3 years

Intervention	mmHg (Mean)
IOP Before Treatment	14
IOP After Treatment	16

Neutralizing Antibody Assay

The mean of Neutralizing antibody assay of 8 patients before and after treatment (NCT01267422)
Timeframe: up to 3 years

Intervention	titer (Mean)
The Mean of Neutralizing Antibody Assay Before Treatment	0.9221
The Mean of Neutralizing Antibody Assay After Treatment	0.8723

Average RNFL Thickness Througth Optical Coherence Tomography(OCT) Test

Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment (NCT01267422)
Timeframe: Up to 3 years

Intervention	Micrometer (Mean)
	injected eye	uninjected eye
Average RNFL Thickness After Treatment	46.7813	47.9688
Average RNFL Thickness Before Treatment	47.3125	50.1875

Computerized Visual Field(MD: Mean Deviation, the Value Close to 0 Regarded Normal)

MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years

Intervention	dB (Mean)
	injected eye	uninjected eye
Mean MD After Treatment	-23.813	-23.427
Mean MD Before Treatment	-29.377	-28.701

Computerized Visual Field(VFI: Visual Field Index ,the Value Close to 100% Regarded Normal)

VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years

Intervention	Percentage of normal (Mean)
	injected eye	uninjected eye
Mean VFI After Treatment	28	25
Mean VFI Before Treatment	11	10.5

Results of CD3/CD4/CD8 Test

The mean percentage of CD3+/CD4+/CD8+ test before and after treatment (NCT01267422)
Timeframe: up to 6 months

Intervention	Percentage of total cells (Mean)
	Values of CD3+	Values of CD4+	Values of CD8+
The Mean Percentage of CD3+/CD4+/CD8+ After Treatment	53	20	13
The Mean Percentage of CD3+/CD4+/CD8+ Before Treatment	51	26	20

The Best Corrected Visual Acuity(BCVA)

(NCT01267422)
Timeframe: Up to 3 years

Intervention	logMAR (Mean)
	before treament	1 months after treament	3 months after treament	6 months after treament	9 months after treament
BCVA of Treated Eyes	1.69	1.58	1.38	1.23	1.27
BCVA of Un-treated Eyes	1.40	1.36	1.31	1.20	1.23

Trials

1 trial available for lactic acid and Hereditary Optic Atrophy

Article	Year
Respiratory chain function in Leber's hereditary optic neuropathy: lack of correlation with clinical disease. Journal of inherited metabolic disease, 1993, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; DNA; Electron Transport; Female; Fibroblasts; Humans; Lactates; Lactic Acid	1993

Other Studies

4 other studies available for lactic acid and Hereditary Optic Atrophy

Article	Year
Abnormal lactate after effort in healthy carriers of Leber's hereditary optic neuropathy. Journal of neurology, neurosurgery, and psychiatry, 1995, Volume: 58, Issue:5 Topics: DNA Mutational Analysis; Exercise; Heterozygote; Humans; Lactates; Lactic Acid; Optic Atrophies, Her	1995
Leber's congenital amaurosis associated with mitochondrial dysfunction. Journal of child neurology, 1996, Volume: 11, Issue:2 Topics: Age of Onset; Blindness; Child, Preschool; DNA, Mitochondrial; Female; Humans; Lactic Acid; Muscle,	1996
A case of Leber's hereditary optic neuropathy with elevated blood levels of lactate and pyruvate. The British journal of ophthalmology, 1997, Volume: 81, Issue:5 Topics: Adult; Humans; Lactic Acid; Male; Optic Atrophies, Hereditary; Pyruvic Acid	1997
Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. Journal of the neurological sciences, 1998, Oct-08, Volume: 160, Issue:2 Topics: Adult; Africa, Northern; Biopsy, Needle; DNA, Mitochondrial; Electron Transport Complex IV; Humans;	1998